论文部分内容阅读
目的:观察、研究重组人干扰素α-2b用于治疗慢性丙型肝炎患者的临床效果。方法:将最近几年因丙肝而来我院医治的30例患者随机分为2组,α-2b干扰素治疗组和常规治疗组。α-2b干扰素治疗组的患者需服用重组人干扰素α-2b注射液(安福隆),同时口服利巴韦林片配合治疗,每个疗程3个月,共设2个疗程,患者的每天服用量是500MU。同时常规治疗组的患者需服用门冬氨酸、维他命C作为对照治疗。治疗结束后用患者血清中的HCV-RNA、外周血单个核细胞内的HCV-RNA以及抗一HCV三项指标作为疗效评价指标。结果:2个疗程治疗结束后,α-2b干扰素治疗组患者的三项疗效评价指标的转阴率均远远高于常规治疗组,二者相比有显著差异。结论:α-2b干扰素在用于治疗慢性丙肝时,相较于常规治疗方法,其疗效显著。
Objective: To observe and study the clinical effect of recombinant human interferon α-2b in the treatment of chronic hepatitis C patients. Methods: Thirty patients with hepatitis C from our hospital in recent years were randomly divided into 2 groups, α-2b interferon treatment group and conventional treatment group. α-2b interferon treatment group patients taking recombinant human interferon α-2b injection (An Fulong), while oral ribavirin tablets with the treatment of each course of 3 months, a total of 2 courses, the patient’s The daily dose is 500MU. At the same time, patients in routine treatment group should take aspartate and vitamin C as control. HCV-RNA in the serum of patients, HCV-RNA in peripheral blood mononuclear cells and three anti-HCV indicators were used as evaluation indicators after treatment. Results: After two courses of treatment, the negative conversion rates of the three efficacy evaluation indexes of patients in the α-2b interferon treatment group were much higher than those in the conventional treatment group. There was a significant difference between the two groups. Conclusions: α-2b interferon is significantly effective in the treatment of chronic hepatitis C compared with conventional treatment.